INDV Stock Forecast & Price Target

Indivior Pharmaceuticals has demonstrated strong growth potential, with the number of patients on Sublocade treatment increasing to approximately 171,500 in Q3 2025, reflecting an 8% rise year-over-year, and a notable rise in prescribers by 11%. The company has revised its worldwide sales guidance for Sublocade to a range of $825 million to $845 million, indicating an annual growth rate of around 10% at the midpoint. Additionally, there is optimism regarding the peak sales potential for Sublocade, estimated between $1.5 billion and $2 billion, supported by a favorable long-term EBITDA CAGR and ongoing expense control.

Indivior Pharmaceuticals is experiencing a significant reduction in its operational footprint, transitioning from commercial support in approximately 40 countries for Sublocade to just four, indicating a concerning decline in market reach. The company's decision to discontinue commercial support for Opvee highlights a lack of product synergy and a potential narrowing of its treatment portfolio, which could hinder overall revenue growth. Additionally, consensus forecasts predict a revenue decline of around 6.5% for 2026, raising doubts about the sustainability of growth, despite potential improvements in EBITDA margins driven by Sublocade's performance.